arrow
C

Clara Saldarriaga

pontificia bolivariana university
H指数:23
被引数:4,273

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

vericiguat在射血分数降低的慢性心力衰竭中的血压、安全性及临床疗效:VICTOR试验的启示

2025-09-011
PRE
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

维利西呱用于射血分数降低的心力衰竭患者:VICTORIA和VICTOR试验的个体参与者数据分析

2025-08-300
OAAI
Gender gap in medicine: a call to action for Latin America

医学领域的性别差距:拉丁美洲的行动呼吁

2025-08-300
OAAI
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR

维利西呱对HFrEF代偿期门诊患者心力衰竭恶化的影响:来自VICTOR研究的见解

JACC
IF0
2025-08-270
PREAI
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Butler, J.; Fioretti, F.; McMullan, C.J.; Anstrom, K.J.; Barash, I.; Bonaca, M.P.; Borentain, M.; Corda, S.; Teixeira, P.P.; Ezekowitz, J.A.; 等. 维利卡格特与射血分数降低的心力衰竭患者的死亡率:VICTOR试验。Eur. Heart J. 2025, ehaf655. [Google Scholar] [CrossRef]

2025-08-0116
OA
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

非奈利酮在射血分数改善的心力衰竭中的应用:FINEARTS-HF随机临床试验

2025-05-210
PRE
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
2025-01-011
OA
Marked Global Differences in Mortality in Male Patients with COVID-19: An Analysis of the CARDIO COVID 19-20 and WHF COVID-19 CVD Studies
2025-01-010
OAAI
Diagnostic and therapeutic practice for Heart Failure with preserved ejection fraction around the world: An international survey
2024-12-010
PRE
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial
2024-10-300
OA
Applicability of heart failure clinical practice guidelines in low- and middle-income countries

心力衰竭临床实践指南在低收入和中等收入国家的适用性

2024-10-250
OA
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2024-10-2443
PRE
Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey
2024-10-010
OA